Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction of anti-TNF therapy in axial spondyloarthritis patients in sustained remission
2011-005871-18Phase 4Completed
- Sponsor
- Spanish Clinical Pharmacology Society
- Start
- Dec 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab, etanercept, golimumab and infliximab in axial spondyloarthritis (axSpA) (2 arms), sponsored by Spanish Clinical Pharmacology Society. Started Dec 2011; status: completed.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2011-005871-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005871-18.